Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallumsetla, Nishanth, Paludo, Jonas, Kapoor, Prashant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644179/
https://www.ncbi.nlm.nih.gov/pubmed/26609233
http://dx.doi.org/10.2147/TCRM.S72943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644179/
https://www.ncbi.nlm.nih.gov/pubmed/26609233
http://dx.doi.org/10.2147/TCRM.S72943

Ejemplares similares